|
Re: Patient Years & MACE rate Question
|
8
|
Resverlogix Corp.
|
Jul 11, 2019 08:33AM
|
|
This is a Drug for people at the end of their life...CHF and advanced kidney disease...so is Dementia next?
|
8
|
Resverlogix Corp.
|
Nov 18, 2019 09:44AM
|
|
Re: In the near term we will continue our multi-point approach to progressing our corporate commercial value. This approach involves aggressive explorator
|
9
|
Resverlogix Corp.
|
Dec 06, 2019 09:34AM
|
|
Re: Comments on the AGM
|
9
|
Resverlogix Corp.
|
Nov 09, 2019 11:25AM
|
|
Re: Could there be another shoe waiting to drop?
|
9
|
Resverlogix Corp.
|
May 20, 2019 02:01PM
|
|
Re: eGFR and Cognition?
|
9
|
Resverlogix Corp.
|
Nov 23, 2019 08:15PM
|
|
Re: Potential market
|
9
|
Resverlogix Corp.
|
Nov 17, 2019 04:11PM
|
|
Re: What will happen if warrant holders convert and then sell?
|
9
|
Resverlogix Corp.
|
Dec 01, 2019 06:50AM
|
|
Re: Clarification on BETonMACE baseline data
|
9
|
Resverlogix Corp.
|
Sep 04, 2019 04:03PM
|
|
RVX gets Breakthrough Therapy Designation!!!
|
10
|
Resverlogix Corp.
|
Feb 03, 2020 07:34AM
|
|
Pfizer's plans for research: sounds like RVX!
|
10
|
Resverlogix Corp.
|
Jan 29, 2020 11:45AM
|
|
Re: New share price contest for end of year 2019
|
11
|
Resverlogix Corp.
|
Nov 20, 2019 10:18AM
|
|
Seeking Alpha Report on what Breakthrough Therapy means for a company
|
13
|
Resverlogix Corp.
|
Feb 07, 2020 10:46PM
|
